Jazz Pharmaceuticals (JAZZ) Q2 FY26 earnings call: guidance and Q&A

Inquired about the drivers behind Epidiolex's better-than-expected quarter, specifically asking about inventory movements or new indications.

Management attributed growth to robust underlying demand, 12% volume growth, and focus on the long-term care setting. Noted no significant unusual inventory movements, but mentioned prior year's ex-U.S. pricing adjustments and FX impact as factors.

“This is 12% volume growth, which again, just reflects really good strong demand in both the pediatric and the adult settings, reinforcing our position as the #1 branded antiseizure medication in refractory epilepsy.”

asked by Marc Goodman · answered by Samantha Pearce

Asked about confidence in zanidatamab approval before or on the PDUFA date and confidence in the doublet arm hitting on OS with the upcoming interim analysis.

Management expressed high confidence in approval on or before the PDUFA date, citing productive engagement with the FDA. For the doublet arm, they noted strong results from the first interim and increased power for the second interim, expressing optimism.

“So we've been productively engaged with the FDA, and it does feel like we're in the home stretch. We're highly confident in the approval. I would still say on or before the PDUFA date, and we are certainly ready to launch.”

asked by Jessica Fye · answered by Robert Iannone

Asked if Xywav's first-half strength implies a re-basing for 2027 or if it's due to delayed generics, suggesting a potential headwind in 2027.

Management highlighted Xywav's unique low-sodium benefits and slower-than-anticipated generic uptake, leading to raised 2026 guidance. Expressed increasing confidence for Xywav's position in the market going forward, but deferred specific 2027 guidance.

“Probably leading to even slower uptake of generics than we might have originally anticipated, which is leading to some of the raise we have for the guidance this year. I would say that continues to put us in a really strong position as we think about the go-forward discussions that we might have with payers as well.”

asked by Jason Gerberry · answered by Philip Johnson

Inquired about the Epidiolex strategy, including new studies and the capsule formulation, asking if it grows the opportunity or defends against future entrants, and if the capsule extends IP.

Management stated the capsule formulation allows greater penetration into the adult market and improves accessibility/compliance, driving incremental opportunity. Clarified that the capsule launch does not impact IP or ANDA agreements, with method-of-use patents extending durability into the late 2030s.

“The capsule launch does not have any impact on IP. It does not have any impact on our ANDA agreements that extend the durability, as I mentioned, out to the 2030s -- the very late 2030s our patent estate contains method of use patents that are relevant to all approved indications, and that's relevant to both the existing oral solution as well as the new capsule formulation.”

asked by Leonid Timashev · answered by Renée Galá

Asked about the long-term growth trajectory of Xywav in IH, considering future competition from Lumryz and orexin agonists.

Management emphasized Xywav's low-sodium differentiation, which is durable and resonates with physicians due to cardiometabolic comorbidities in IH/narcolepsy patients. Stated Xywav addresses the root cause of disrupted nighttime sleep, making it a cornerstone therapy, potentially complemented by daytime agents like orexins. Highlighted early penetration in the IH market with significant room for growth.

“The differentiation for Xywav is twofold. And perhaps one of the most kind of important things about Xywav is the low sodium. And of course, that's going to be a component of its differentiation that will go beyond just another product having an IH indication.”

asked by David Amsellem · answered by Samantha Pearce